📰 Full Story
Stryker Corp reported weaker-than-expected first-quarter results on April 30, 2026, as a late‑Q1 cyber incident disrupted operations and delayed shipments.
Revenue was $6.02 billion versus analyst expectations near $6.34–6.35 billion; adjusted EPS fell to $2.60, missing forecasts of about $2.98.
Organic sales rose 2.4% (U.S. 1.9%, international 3.9%). Segment results were mixed: MedSurg and neurotechnology sales of $3.21 billion missed estimates, while orthopedics rose 6.3% to $2.81 billion and beat expectations.
Management reiterated full‑year guidance of $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth, saying systems were restored and much of the lost Q1 activity should be recovered through H2.
The company highlighted record Mako robotic installations, a new Ortho Tech business and the planned acquisition of Amplitude Vascular Systems in Q2.
The cyberattack was publicly linked by a group claiming responsibility, an attribution Stryker and Reuters did not independently verify.
Shares slipped in subsequent trading and numerous brokerages cut price targets, while insiders sold roughly $181.9 million of stock in the past three months.






💬 Commentary